Compositions and methods for detecting and/or treating inflammation

Abstract

The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.

1 .- 21 . (canceled) 
     
     
         22 . A composition comprising a P2Y14 inhibitor in a therapeutically effective amount to treat or prevent renal inflammation. 
     
     
         23 . The composition of  claim 22 , wherein the P2Y14 inhibitor is 4-((piperidin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid (PPTN). 
     
     
         24 . The composition of  claim 22 , wherein the composition is suitable for administration by a route selected from the group consisting of parenteral, intravenous, intralesional, intratumoral, subcutaneous, intramuscular, and intraperitoneal. 
     
     
         25 . The composition of  claim 22 , wherein the composition is suitable for administration by a mode selected from the group consisting of injection and infusion. 
     
     
         26 . The composition of  claim 22 , wherein the composition is suitable for delivery in an organ-specific delivery device. 
     
     
         27 . The composition of  claim 26 , wherein the delivery device is a renal catheter. 
     
     
         28 . The composition of  claim 22 , wherein the composition is suitable for delivery into renal circulation. 
     
     
         29 . The composition of  claim 22 , wherein the renal inflammation is associated with a condition selected from the group consisting of acute kidney injury, chronic renal failure, glomerulonephritis, heterologous nephrotoxic nephritis, an immune-related disease, nephropathy, pyelonephritis, and sclerosis of the glomerulus. 
     
     
         30 . The composition of  claim 29 , wherein the renal inflammation is associated with acute kidney injury. 
     
     
         31 . The composition of  claim 22 , wherein the renal inflammation is early stage. 
     
     
         32 . A composition comprising a P2Y14 inhibitor in a therapeutically effective amount to treat or prevent acute kidney injury. 
     
     
         33 . The composition of  claim 32 , wherein the P2Y14 inhibitor is PPTN. 
     
     
         34 . The composition of  claim 32 , wherein the composition is suitable for administration by a route selected from the group consisting of parenteral, intravenous, intralesional, intratumoral, subcutaneous, intramuscular, and intraperitoneal. 
     
     
         35 . The composition of  claim 32 , wherein the composition is suitable for administration by a mode selected from the group consisting of injection and infusion. 
     
     
         36 . The composition of  claim 32 , wherein the composition is suitable for delivery in an organ-specific delivery device. 
     
     
         37 . The composition of  claim 36 , wherein the delivery device is a renal catheter. 
     
     
         38 . The composition of  claim 32 , wherein the composition is suitable for delivery into renal circulation.